WILMINGTON, NC--(Marketwire - August 11, 2008) - Gene Express, Inc. today announced that it has signed three definitive agreements with NeoGenomics Laboratories to license the SEM Center and StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) Technology. NeoGenomics will support Gene Express in its FDA validation of its Lung Cancer Risk Prediction and BCR/ABL tests. The agreements will also allow NeoGenomics to commercialize Gene Express diagnostic tests, validate future Gene Express technology to fulfill FDA requirements, and utilize StaRT-PCR for their own commercial activities. These agreements succeed in establishing a key validation and commercialization partnership between Gene Express and NeoGenomics.
